Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells $72,471.48 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 24,819 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $2.92, for a total value of $72,471.48. Following the sale, the chief executive officer now directly owns 5,676,331 shares in the company, valued at approximately $16,574,886.52. This trade represents a 0.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Paul Badawi also recently made the following trade(s):

• On Thursday, January 2nd, Paul Badawi sold 12,236 shares of Sight Sciences stock. The stock was sold at an average price of $3.60, for a total value of $44,049.60.

Sight Sciences Stock Performance

NASDAQ SGHT opened at $2.88 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. Sight Sciences, Inc. has a 1-year low of $2.67 and a 1-year high of $8.45. The company has a market cap of $146.19 million, a PE ratio of -2.82 and a beta of 2.57. The stock’s 50 day simple moving average is $3.57 and its 200-day simple moving average is $5.33.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $20.16 million for the quarter, compared to analysts’ expectations of $20.41 million. As a group, equities research analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current fiscal year.

Institutional Trading of Sight Sciences

Several large investors have recently bought and sold shares of SGHT. Bank of New York Mellon Corp lifted its position in Sight Sciences by 70.5% during the second quarter. Bank of New York Mellon Corp now owns 102,461 shares of the company’s stock worth $683,000 after buying an additional 42,383 shares in the last quarter. Rhumbline Advisers raised its position in shares of Sight Sciences by 40.1% during the 2nd quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock valued at $272,000 after buying an additional 11,671 shares during the period. American Century Companies Inc. lifted its holdings in Sight Sciences by 31.1% in the second quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after acquiring an additional 8,527 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Sight Sciences during the second quarter worth $95,000. Finally, Long Focus Capital Management LLC raised its position in Sight Sciences by 86.9% in the second quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock valued at $3,739,000 after purchasing an additional 260,594 shares during the period. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. UBS Group initiated coverage on shares of Sight Sciences in a research note on Friday, December 6th. They issued a “buy” rating and a $5.50 target price for the company. Piper Sandler reiterated a “neutral” rating and issued a $5.50 price objective (down previously from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Morgan Stanley dropped their target price on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, November 11th. Citigroup reduced their target price on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Tuesday, January 14th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.72.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.